Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 05:56:50 +0200Fri, 21 Jun 2024 14:46:00 +0200Triumeq : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-2754-en_1.pdfTriumeq : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-2754-en_1.pdfFri, 21 Jun 2024 14:46:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Triumeq, abacavir sulfate / dolutegravir sodium / lamivudine, Date of authorisation: 31/08/2014, Revision: 33, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/triumeqHuman medicines European public assessment report (EPAR): Triumeq, abacavir sulfate / dolutegravir sodium / lamivudine, Date of authorisation: 31/08/2014, Revision: 33, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/triumeqFri, 21 Jun 2024 11:18:00 +0200Human medicine